These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 32078298)

  • 1. Role of α-Synuclein Regions in Nucleation and Elongation of Amyloid Fiber Assembly.
    Gallardo J; Escalona-Noguero C; Sot B
    ACS Chem Neurosci; 2020 Mar; 11(6):872-879. PubMed ID: 32078298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of enhanced aggregation and fibril formation of Parkinson's disease-related variants of α-synuclein.
    Ohgita T; Namba N; Kono H; Shimanouchi T; Saito H
    Sci Rep; 2022 Apr; 12(1):6770. PubMed ID: 35474118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structures and free energy landscapes of the A53T mutant-type α-synuclein protein and impact of A53T mutation on the structures of the wild-type α-synuclein protein with dynamics.
    Coskuner O; Wise-Scira O
    ACS Chem Neurosci; 2013 Jul; 4(7):1101-13. PubMed ID: 23607785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanistic insight into the relationship between N-terminal acetylation of α-synuclein and fibril formation rates by NMR and fluorescence.
    Kang L; Janowska MK; Moriarty GM; Baum J
    PLoS One; 2013; 8(9):e75018. PubMed ID: 24058647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C-terminal α-synuclein truncations are linked to cysteine cathepsin activity in Parkinson's disease.
    McGlinchey RP; Lacy SM; Huffer KE; Tayebi N; Sidransky E; Lee JC
    J Biol Chem; 2019 Jun; 294(25):9973-9984. PubMed ID: 31092553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Tyr to Ala mutations on alpha-synuclein fibrillation and structural properties.
    Ulrih NP; Barry CH; Fink AL
    Biochim Biophys Acta; 2008 Oct; 1782(10):581-5. PubMed ID: 18692132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic Amyloid Switch Triggered by Early Heterotypic Oligomerization of Intrinsically Disordered α-Synuclein and Tau.
    Bhasne K; Sebastian S; Jain N; Mukhopadhyay S
    J Mol Biol; 2018 Aug; 430(16):2508-2520. PubMed ID: 29704492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Insights into the Misfolding and Dimerization Dynamics of the Full-Length α-Synuclein from Atomistic Discrete Molecular Dynamics Simulations.
    Zhang Y; Wang Y; Liu Y; Wei G; Ding F; Sun Y
    ACS Chem Neurosci; 2022 Nov; 13(21):3126-3137. PubMed ID: 36278939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modification of C Terminus Provides New Insights into the Mechanism of α-Synuclein Aggregation.
    Afitska K; Fucikova A; Shvadchak VV; Yushchenko DA
    Biophys J; 2017 Nov; 113(10):2182-2191. PubMed ID: 28939194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Solution conditions determine the relative importance of nucleation and growth processes in α-synuclein aggregation.
    Buell AK; Galvagnion C; Gaspar R; Sparr E; Vendruscolo M; Knowles TP; Linse S; Dobson CM
    Proc Natl Acad Sci U S A; 2014 May; 111(21):7671-6. PubMed ID: 24817693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perturbation in Long-Range Contacts Modulates the Kinetics of Amyloid Formation in α-Synuclein Familial Mutants.
    Ranjan P; Kumar A
    ACS Chem Neurosci; 2017 Oct; 8(10):2235-2246. PubMed ID: 28759722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The chaperonin CCT inhibits assembly of α-synuclein amyloid fibrils by a specific, conformation-dependent interaction.
    Sot B; Rubio-Muñoz A; Leal-Quintero A; Martínez-Sabando J; Marcilla M; Roodveldt C; Valpuesta JM
    Sci Rep; 2017 Jan; 7():40859. PubMed ID: 28102321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controlling aggregation propensity in A53T mutant of alpha-synuclein causing Parkinson's disease.
    Kumar S; Sarkar A; Sundar D
    Biochem Biophys Res Commun; 2009 Sep; 387(2):305-9. PubMed ID: 19580781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of tyrosine residues on α-synuclein fibrillation.
    Pirc K; Škarabot M; Pogačnik L; Žerovnik E; Poklar-Ulrih N
    Acta Chim Slov; 2015; 62(1):181-9. PubMed ID: 25830974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insights into the Molecular Mechanisms of Alzheimer's and Parkinson's Diseases with Molecular Simulations: Understanding the Roles of Artificial and Pathological Missense Mutations in Intrinsically Disordered Proteins Related to Pathology.
    Coskuner-Weber O; Uversky VN
    Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29364151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from alpha-synuclein in vitro.
    Cohlberg JA; Li J; Uversky VN; Fink AL
    Biochemistry; 2002 Feb; 41(5):1502-11. PubMed ID: 11814343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Macromolecular crowding modulates α-synuclein amyloid fiber growth.
    Horvath I; Kumar R; Wittung-Stafshede P
    Biophys J; 2021 Aug; 120(16):3374-3381. PubMed ID: 34242594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural Insights into α-Synuclein Fibril Polymorphism: Effects of Parkinson's Disease-Related C-Terminal Truncations.
    Ni X; McGlinchey RP; Jiang J; Lee JC
    J Mol Biol; 2019 Sep; 431(19):3913-3919. PubMed ID: 31295458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of conformational and dynamic properties of natively unfolded human and mouse alpha-synuclein ensembles by NMR: implication for aggregation.
    Wu KP; Kim S; Fela DA; Baum J
    J Mol Biol; 2008 May; 378(5):1104-15. PubMed ID: 18423664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The aggregation and fibrillation of alpha-synuclein.
    Fink AL
    Acc Chem Res; 2006 Sep; 39(9):628-34. PubMed ID: 16981679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.